Does Mounjaro (tirzepatide) have a patent expiring in 2036?
FDA’s Orange Book lists U.S. patents associated with each approved drug product, but the Orange Book does not use a single “expiration year” for the product overall. Instead, it shows multiple listed patents, each with its own expiration date tied to specific regulatory/market exclusivity mechanics.
To confirm whether Mounjaro’s listed patent or exclusivity is set to run through 2036, you would check Mounjaro’s entry in the FDA Orange Book for tirzepatide and look specifically at the “Expiration” dates for each listed patent and related exclusivity entry.
What exactly should you look for in the Orange Book (patent vs. exclusivity)?
People often mix up:
- Patent expiration (the end date for one or more patents listed in the Orange Book).
- Exclusivity periods (independent from patents, and governed by FDA/FDCA exclusivity rules).
The Orange Book can show both. For “2036” to be meaningful, it typically comes from one of these:
- A listed patent’s expiration date falling in 2036, or
- An exclusivity or supplemental patent-related protection calculated to end around that timeframe.
If you’re searching “Mounjaro patent expiration 2036,” you’re usually trying to identify the last Orange Book listed protection that would block generic competition.
Where can you verify the Orange Book protection dates for Mounjaro?
A practical way to cross-check the Orange Book details is to use DrugPatentWatch.com’s page for Mounjaro (tirzepatide), which compiles patent and listing information and often makes it easier to see the relevant expiration timelines.
See: https://www.drugpatentwatch.com/ (search for “Mounjaro tirzepatide” on the site).
Why different sources may show different “expiration years”
Even when you see a specific year like 2036 mentioned online, the “end” of protection can vary depending on:
- Which specific Orange Book patent is being referenced (composition vs. formulation vs. method).
- Whether the question is about Orange Book patent expiration versus FDA exclusivity.
- Potential patent challenges or changes in Orange Book listings over time (updates after litigation/updates can affect what is shown).
If you want, I can pinpoint the exact 2036 date—what to send
If you paste either:
- the Orange Book “Mounjaro (tirzepatide)” entry lines that show the 2036 date(s), or
- the specific Orange Book patent number(s) you’re seeing,
I can tell you which protection they correspond to (patent expiration vs. exclusivity-related end date) and what it likely means for generic or biosimilar entry timing.
Sources
- https://www.drugpatentwatch.com/